Navigation Links
Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043

DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Perrigo Company plc, a public limited company incorporated under the laws of Ireland (the "Company"), today announced that it is offering to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior Notes due 2016 (the "2016 Exchange Notes"), $600,000,000 of its new 2.30% Senior Notes due 2018 (the "2018 Exchange Notes"), $800,000,000 of its new 4.00% Senior Notes due 2023 (the "2023 Exchange Notes") and $400,00,000 of its new 5.30% Senior Notes due 2043 (the "2043 Exchange Notes" together with the 2016 Exchange Notes, the 2018 Exchange Notes and the 2023 Exchange Notes, the "Exchange Notes"), which will be registered under the Securities Act of 1933, as amended, for a like principal amount of its 1.30% Senior Notes due 2016 (the "2016 Notes"), 2.30% Senior Notes due 2018 (the "2018 Notes"), 4.00% Senior Notes due 2023 (the "2023 Notes") and 5.30% Senior Notes due 2043 (the "2043 Notes" together with the 2016 Notes, the 2018 Notes and the 2023 Notes, the "Outstanding Notes" and together with the Exchange Notes, the "Notes"), pursuant to the terms of a Registration Rights Agreement, dated November 8, 2013, which the Company entered into with the initial purchasers of the Outstanding Notes in connection with the Company's offering of the Outstanding Notes.

The Exchange Notes to be issued in the Exchange Offer will be substantially identical to the Outstanding Notes, except that the Exchange Notes have been registered under the federal securities laws, are not subject to transfer restrictions, are not entitled to registration rights and will not provide for the payment of additional interest under circumstances relating to the timing of the Exchange Offer.

The Exchange Offer will expire at 5:00 pm, New York City time on September 30, 2014, unless extended by the Company. Valid tenders of the Outstanding Notes must be made, and may be withdrawn at any time, before the Exchange Offer expires.

Wells Fargo Bank, National Association, the trustee under the indenture governing the Notes, is serving as the exchange agent in connection with the Exchange Offer. Questions or requests for documents relating to the Exchange Offer should be directed to Wells Fargo Bank, National Association at (800) 344-5128.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities. The Exchange Offer is being made only pursuant to a prospectus and the related letter of transmittal and only to such persons and in such jurisdictions as is permitted under applicable law. For instructions on how to participate in the Exchange Offer and the consequences to holders who do not participate in the Exchange Offer, see the prospectus filed with the Securities and Exchange Commission in connection with the Exchange Offer.

About Perrigo Company plc

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products®" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (

Forward-Looking Statements

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Logo -



SOURCE Perrigo Company plc
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
3. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
4. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
7. Perrigo Company To Present At The William Blair Growth Stock Conference
8. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
9. Perrigo Company Announces Quarterly Dividend
10. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
11. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... According to an ... groups has filed a discrimination claim against the U.S. Department of Health and Human ... Affordable Care Act (ACA) plans are breaking the clause in the law prohibiting the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... ... , ... Growth in medical payments per workers’ compensation claim in Louisiana slowed ... nonhospital care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... medical payments per claim with more than seven days of lost time continued to ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced ... Bridge Business Awards under the New Products and Services category for its innovative ... sample management software that helps labs organize data and track samples with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
Breaking Medicine News(10 mins):